Pay in 4 interest-free payments of $11.25 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway
Odanacatib displays compartment-specific effects on trabecular versus cortical bone formation
but not activity of other SCF complexes
54 nM for the inhibition of survivin promoter activity
PI3K-alpha (IC50=0
KPT-330 - CAS# 1393477-72-9 009 is an orally available cyclin-dependentKPT 330, CAS No. 1393477 72 9, is an orally bioavailable, potent and selective XPO1 CRM1 Inhibitor. KPT 330 is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. KPT 330 potentiates the antitumor activity of gemcitabine in human pancreatic cancer through inhibition of tumor growth, depletion of the antiapoptotic proteins, and induction of apoptosis. KPT 330 has strong activity against primary
US$ 135.00
US$ 65.00
US$ 129.00
US$ 129.00
US$ 129.00
US$ 129.00
US$ 139.00
US$ 129.00
US$ 139.00
US$ 139.00
US$ 129.00
US$ 129.00
US$ 139.00